MHS552

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Lupus Erythematosus, SystemicType 1 Diabetes Mellitus

Phase 1

Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)

TerminatedNCT05203419

Novartis PharmaceuticalsLupus Erythematosus, Systemic

Start: 2022-03-15End: 2023-06-04Updated: 2024-10-09

Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus

WithdrawnNCT05272059

Novartis PharmaceuticalsType 1 Diabetes Mellitus

Start: 2023-09-01End: 2025-04-14Updated: 2023-04-07